MYGN
$4.78
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test,...
Recent News
2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.
3 Reasons to Sell MYGN and 1 Stock to Buy Instead
Shareholders of Myriad Genetics would probably like to forget the past six months even happened. The stock dropped 31.8% and now trades at $5.24. This may have investors wondering how to approach the situation.
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc
Check out the companies making headlines yesterday:
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 6.9% in the afternoon session after its President and CEO, Samraat Raha, purchased a significant amount of company stock. According to filings, Raha bought 40,000 shares for a total of approximately $200,000, at an average price near $5.00 per share. This purchase increased his direct ownership to 493,104 shares. Such a large buy from a top executive is often viewed by investors as a strong vote of confidence in the company's